 |
|
| |
Astellas Pharma Canada, Inc. inherited its existence and spirit from Fujisawa Canada, Inc. (on April 1, 2005, Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. merged to form Astellas Pharma Inc.). Astellas contributes to healthier lives for people around the world by exploring the frontiers of human health and disease. Astellas is the manufacturer of Protopic® (tacrolimus) ointment, the world’s first steroid-free topical therapy for atopic dermatitis. We are proud to partner with dermatologists, researchers and clinical trial sites in Canada and around the world. Together we seek new ways to bring relief to those who suffer from diseases of the skin – diseases that often affect the very core of how people feel about themselves. We’re committed to dermatology, with a separate research and development division dedicated exclusively to the field. Our history of collaborating with investigators around the world provides an ideal environment to study compounds that have the potential for significant breakthroughs - and to generate and publish the resulting data. In fact, with more than 19,000 patients, the Protopic® clinical trial program conducted by Astellas is the most extensive in the history of dermatology. These efforts are motivated by a sincere desire to advance patient care. By working with the dermatology community, we can effectively improve the future for those who suffer from skin disease.
Click here to close this window
|
